Table 1 The comparison of clinical and genetic features between LINC00649-high and LINC00649-low groups. A total of 145 patients from TCGA and 451 patients form BeatAML database were included. The molecular and cytogenetic risk of LINC00649-low group is more adverse than that of LINC00649-high group (p < 0.001)
From: LINC00649 underexpression is an adverse prognostic marker in acute myeloid leukemia
| Â | TCGA | beatAML | ||||
|---|---|---|---|---|---|---|
LINC00649-low group (n = 72) | LINC00649-high group (n = 73) | p value | LINC00649-low group (n = 225) | LINC00649-high group (n = 226) | p value | |
Age (year) | 55.21 ± 2.011 | 54.47 ± 2.137 | 0.81 | 59.81 ± 1.055 | 53.62 ± 1.356 | 0.049 |
Gender | Â | Â | 0.589 | Â | Â | 0.775 |
 Female | 27 | 31 |  | 95 | 98 |  |
 Male | 35 | 31 |  | 130 | 127 |  |
Race | Â | Â | 0.838 | Â | Â | 0.801 |
 White | 47 | 45 |  | 39 | 37 |  |
 Other races | 15 | 17 |  | 186 | 188 |  |
Mutation count | 9.82 ± 0.624 | 9.77 ± 0.803 | 0.962 | NA | NA |  |
Risk stratification of cytogenetics | Â | 0.001 | Â | Â | NA | |
 Good | 0 | 15 |  | NA | NA |  |
 Intermediate | 48 | 28 |  | NA | NA |  |
 Poor | 14 | 19 |  | NA | NA |  |
Risk stratification of molecular mutation | Â | 0.001 | Â | Â | 0.002 | |
 Good | 0 | 15 |  | 99 | 70 |  |
 Intermediate | 45 | 28 |  | 44 | 73 |  |
 Poor | 17 | 19 |  | 82 | 82 |  |
WBC | 47.498 ± 5.091 | 22.705 ± 5.040 | 0.001 | 34.807 ± 2.979 | 27.615 ± 3.465 | 0.112 |